Elevated Blood Pressure in HIV-Infected Individuals Receiving Highly Active Antiretroviral Therapy

作者：Dominic Cheung Chow, Scott A. Souza, Randi Chen, Suzanne M. Richmond-Crum, Andy Grandinetti, Cecilia M. Shikuma · 发表于：HIV Clinical Trials · 年份：2003 · DOI：10.1310/5e7q-pgwb-16ue-j48u · 被引用次数：87 · 研究领域：HIV-related health complications and treatments、HIV/AIDS drug development and treatment、Blood Pressure and Hypertension Studies

OBJECTIVE: We examined the effects of antiretroviral regimens on blood pressure (BP). METHOD: This retrospective study examined systolic and diastolic BP (SBP and DBP) measurements among participants of a State of Hawaii Department of Health program from January 1995 to July 2001. The change in BP during four consecutive 6-month visits was estimated using linear regression and was interpreted as the change in BP per year. BP changes among the antiretroviral treatment groups were compared to untreated controls. RESULTS: Of 1,601 patients identified, 286 met the criteria for inclusion. After adjustment for baseline age, BP, and CD4+ count, there was an increase in SBP by 4.71 mmHg/year (p =.005) and DBP by 2.26 mmHg/year (p =.076) among patients initiating HAART. Among these patients, an increase of 4.75 mmHg/year in SBP (p =.002) and 1.96 mmHg/year in DBP (p =.042) was seen with HAART regimens containing a protease inhibitor (PI) but no nonnucleoside reverse transcriptase inhibitor (NNRTI). In NNRTI-containing HAART regimens without PIs, an increase of 3.21 mmHg/year in SBP (p =.011) and 2.62 mmHg/year in DBP (p =.050) was observed. No significant BP changes were noted with patients on regimens containing only nucleoside reverse transcriptase inhibitors (NRTIs). CONCLUSION: The use of NNRTI- or PI-containing HAART is associated with elevation of both SBP and DBP in HIV-infected individuals.